Classification
- Anatomical main groupJAnti-infectives for systemic use
- Therapeutic subgroupJ01
- Pharmacological subgroupJ01D
- Chemical subgroupJ01DH
- Chemical substanceJ01DH51Imipenem and cilastatin
Where it is registered
Each register with its number of medicines and a few of them.
All medicines with Imipenem + cilastatina
Every register, a page at a time. Strengths and packs are on each medicine’s page.
46 results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| imipenem + cilastatinaCombination | Brazil | Authorised | Antibióticos do Brasil Ltda | ||
| imipenem + cilastatinaCombination | Brazil | Authorised | Instituto Biochimico Indústria Farmacêutica Ltda | ||
| Imipenem e Cilastatina Steriscience | Italy | Soluzione iniettabile o per infusione | Authorised | Steriscience BV | |
| Imipenem Cilastatina KabiCombination | Italy | Polvere per soluzione per infusione endovenosa | Authorised | Fresenius Kabi Italia S.R.L. | |
| imipenem + cilastatina sódicaCombination | Brazil | Authorised | Midfarma Produtos Farmaceuticos Ltda | ||
| imipenem + cilastatina sódicaCombination | Brazil | Authorised | Ranbaxy Farmacêutica Ltda | ||
| imipenem + cilastatina sódicaCombination | Brazil | Authorised | Newcom Farmaceutica Ltda. | ||
| IMIPENEM/CILASTATINA KABI 500 mg/500 mg POLVO PARA SOLUCION PARA PERFUSION EFGCombination | Spain | 530 mg + 530 mg | polvo para solución para perfusión | Marketed | Fresenius Kabi España, S.A.U. |
| Imipenem/Cilastatina Hikma 500 MG/500 MG Polvo Para Solucion Para Perfusion EfgCombination | Spain | 530 mg + 530 mg | polvo para solución para perfusión | Marketed | Hikma Farmaceutica (Portugal) S.A. |
| IMIPENEM/CILASTATINA AUROVITAS 500 mg/500 mg POLVO PARA SOLUCION PARA PERFUSION EFGCombination | Spain | 500 mg + 500 mg | polvo para solución para perfusión | Marketed | Eugia Pharma (Malta) Limited |
| Imipenem/Cilastatina Noridem 500 MG/500 MG Polvo Para Solucion Para Perfusion EfgCombination | Spain | 530 mg + 530 mg | polvo para solución para perfusión | Authorised | Noridem Enterprises Limited |
| Imipenem/Cilastatina Steriscience 500 MG/500 MG Polvo Para Solucion Para Perfusion EfgCombination | Spain | 530,1 mg + 530,7 mg | polvo para solución para perfusión | Authorised | Steriscience B.V. |
| Imipenem e Cilastatina SunCombination | Italy | Polvere per soluzione per infusione endovenosa | Authorised | Sun Pharmaceutical Industries (Europe) B.V. | |
| Imipenem e Cilastatina HikmaCombination | Italy | Polvere per soluzione per infusione endovenosa | Authorised | Hikma Farmaceutica (Portugal) S.A. | |
| Imipenem e Cilastatina NoridemCombination | Italy | Polvere per soluzione per infusione endovenosa | Authorised | Noridem Enterprises LTD | |
| Imipenem e Cilastatina AurobindoCombination | Italy | Polvere per soluzione per infusione endovenosa | Authorised | Eugia Pharma (Malta) Limited | |
| imipenem + cilastatina sódicaCombination | Brazil | Cancelled | Novafarma Indústria Farmacêutica Ltda | ||
| Imipenem + Cilastatina SodicaCombination | Brazil | Cancelled | Laboratórios Libra do Brasil Ltda | ||
| imipenem + cilastatina sódicaCombination | Brazil | Cancelled | Fresenius Kabi Brasil Ltda | ||
| Imipenem + Cilastatina sódicaCombination | Brazil | Cancelled | Targo Comércio Internacional Limitada | ||
| IMIPENEM/CILASTATINA KABI 500 mg/500 mgCombination | Romania | 500mg/500mg | pulb. pt. sol. perf. | Status unknown | Fresenius Kabi Romania S.R.L. |
| Imipenem and CilastatinCombination | United States | 250MG BASE/VIAL; 250MG/VIAL, 500MG BASE/VIAL; 500MG/VIAL | powder | Marketed | HQ SPCLT Pharma |
| Imipenem/Cilastatina Elc 250 MG/250 MG Polvo Para Solucion Para Perfusion EfgCombination | Spain | 265 mg + 266 mg | polvo para solución para perfusión | Withdrawn | Elc Group S.R.O. |
| Imipenem/Cilastatina Elc 500 MG/500 MG Polvo Para Solucion Para Perfusion EfgCombination | Spain | 530 mg + 532 mg | polvo para solución para perfusión | Withdrawn | Elc Group S.R.O. |
| Taro-Imipenem-CilastatinCombination | Canada | 500 MG / VIAL + 500 MG / VIAL | Powder For Solution | Marketed | Sun Pharma Canada INC |